EPISODE · Aug 22, 2023 · 49 MIN
Creating One Solution For All Skin Types With OneSkin
from Skin Anarchy · host Ekta et al.
Send us Fan MailLet’s ChatJoin us for an interview with the co-founder of OneSkin, Carolina Reis Oliviera, as we dive into the science of the brand’s efficacious formulations and all the reasons they are leading the way to a universal system for healthier skin. OneSkin is a breakthrough line of skin health products powered by longevity science to address the root causes of aging. While many skincare brands make claims about reversing aging, OneSkin is the first company that quantifies the age reversal effect of their products by measuring changes in the skin at the molecular level. By researching the main driver of skin aging, OneSkin developed a new and proprietary peptide, OS-01, which powers OneSkin products. OS-01 is the first peptide proven to reverse aging by reducing the accumulation of aged senescent cells in human skin models. The result? Healthier, biologically younger, more resilient skin for better overall health and longevity. Shop the brand using the information below for a special discount on your purchase:Code: SKINCAREANARCHYOffer: 15% off entire order for new customers Link: https://www/oneskin.coSupport the Show.Follow The Show On All Socials Using The Tag @skincareanarchy Hosted on Acast. See acast.com/privacy for more information.Support the show
What this episode covers
Send us Fan Mail Let’s Chat Join us for an interview with the co-founder of OneSkin, Carolina Reis Oliviera, as we dive into the science of the brand’s efficacious formulations and all the reasons they are leading the way to a universal system for healthier skin. OneSkin is a breakthrough line of skin health products powered by longevity science to address the root causes of aging. While many skincare brands make claims about reversing aging, OneSkin is the first company that qua...
NOW PLAYING
Creating One Solution For All Skin Types With OneSkin
No transcript for this episode yet
Similar Episodes
Feb 11, 2026 ·3m
Nov 3, 2025 ·2m
May 29, 2025 ·3m
Mar 11, 2025 ·2m